{"id":"tmc125-darunavir-ritonavir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1201127","moleculeType":"Small molecule","molecularWeight":"593.74"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Darunavir and Ritonavir are both HIV protease inhibitors that target the protease enzyme, which is essential for the maturation of viral particles. By blocking this enzyme, they prevent the virus from replicating and reduce the viral load in the body.","oneSentence":"TMC125, Darunavir; Ritonavir is a combination of HIV protease inhibitors that work by blocking the protease enzyme, preventing the maturation of viral particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in treatment-experienced adult patients"},{"name":"Treatment of HIV-1 infection in treatment-naive adult patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT00823979","phase":"PHASE2","title":"A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-03-25","conditions":"HIV-1","enrollment":105},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00855335","phase":"PHASE3","title":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2009-04-09","conditions":"HIV, HIV Infections, Pregnancy","enrollment":77},{"nctId":"NCT01199731","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-10-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT00855413","phase":"PHASE4","title":"HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-03","conditions":"Acute HIV Infection, HIV Infections","enrollment":15},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00534352","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-01","conditions":"HIV-1 Infection","enrollment":23},{"nctId":"NCT01118871","phase":"PHASE4","title":"The First Failure Study","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2010-05","conditions":"HIV, HIV Infections","enrollment":3},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT01615601","phase":"","title":"An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":77},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01199939","phase":"PHASE2","title":"A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2010-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":54},{"nctId":"NCT00460746","phase":"PHASE3","title":"Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2007-05","conditions":"HIV","enrollment":10},{"nctId":"NCT01876966","phase":"PHASE1","title":"Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2011-03","conditions":"HIV","enrollment":33},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00867152","phase":"PHASE1","title":"GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-04","conditions":"Healthy Volunteer","enrollment":17},{"nctId":"NCT00782301","phase":"PHASE4","title":"Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593},{"nctId":"NCT00855088","phase":"PHASE1","title":"Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-07","conditions":"HIV/AIDS, HIV Infections","enrollment":13},{"nctId":"NCT00460382","phase":"PHASE2","title":"Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TMC125, Darunavir; Ritonavir","genericName":"TMC125, Darunavir; Ritonavir","companyName":"Tibotec, Inc","companyId":"tibotec-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMC125, Darunavir; Ritonavir is a combination of HIV protease inhibitors that work by blocking the protease enzyme, preventing the maturation of viral particles. Used for Treatment of HIV-1 infection in treatment-experienced adult patients, Treatment of HIV-1 infection in treatment-naive adult patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}